Immunotherapy, which stimulates the patient’s own immune system to
attack cancer, has shown promise in treating a variety of cancer types
with long-term responses. This class of therapy involves a range of
treatments, including checkpoint blockade inhibitors, vaccines and
cell-based therapies.
MD Anderson’s adoptive-cell therapy (ACT) platform, which supports the Moon Shots Program™ was established to develop promising new...
For their role in transforming cancer care, three MD Anderson faculty received the American Society of Clinical Oncology’s Special Awards...
Matching targeted therapies to tumor-specific gene mutations across tumor types improved survival in patients with advanced cancer, compared...
In recent years, five new immunotherapy drugs have been approved to
treat patients diagnosed with urinary cancer. But the drugs, which
held promise for replacing standard chemotherapy treatment, shrank
tumors in only 15 to 20 percent of patients.
An international Phase II trial led by MD Anderson researchers may provide an alternative. The trial showed that treatment with the oral FGFR inhibitor erdafitinib (ERDA) was well-tolerated...
In a small Phase II study of early-stage breast cancer patients with BRCA 1 and 2 mutations, researchers found that more than half of women...
Understanding evolution within cancer cells is a longtime interest for Nicholas Navin, Ph.D., an associate professor of Genetics and Bioinformatics...
In a randomized, Phase II trial led by researchers at MD Anderson, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved...
Eight MD Anderson researchers have been selected as the newest class of Andrew Sabin Family Fellows. As part of the Andrew Sabin Family Fellowship...